- ►diabetesjournals.org DB Savage, GD Tan, CL Acerini, SA Jebb, M Agostini, … - Diabetes, 2003 - Am Diabetes Assoc We previously reported a syndrome of severe hyperinsulinemia and early-onset hypertension
in three patients with dominant-negative mutations in the nuclear hormone receptor peroxisome
proliferator-activated receptor (PPAR)-γ. We now report the results of further detailed ... Cited by 212 - Related articles - BL Direct - All 6 versions
RA Hegele, H Cao, C Frankowski, ST Mathews, T Leff - Diabetes, 2002 - Am Diabetes Assoc Autosomal dominant familial partial lipodystrophy (FPLD) due to mutant LMNA encoding nuclear
lamin A/C is characterized by adipose tissue repartitioning together with multiple metabolic
disturbances, including insulin resistance and dyslipidemia. There is emerging evidence ... Cited by 158 - Related articles - BL Direct - All 6 versions
AK Agarwal, A Garg - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Familial partial lipodystrophies (FPL) are a heterogeneous group of genetic disorders characterized
by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased
preponderance of insulin resistance, diabetes mellitus and dyslipidemia. Recently, lamin ... Cited by 167 - Related articles - All 4 versions
- ►endojournals.org M Agostini, M Gurnell, DB Savage, EM Wood, AG Smith … - Endocrinology, 2004 - Endocrine Soc Loss-of-function mutations in the ligand-binding domain of human peroxisome proliferator-activated
receptor (PPAR ) are associated with a novel syndrome characterized by partial lipodystrophy
and severe insulin resistance. Here we have further characterized the properties of ... Cited by 54 - Related articles - BL Direct - All 4 versions
- ►nih.gov YS Tsai, HJ Kim, N Takahashi, HS Kim, JR … - Journal of Clinical …, 2004 - Am Soc Clin Investig Peroxisome proliferator–activated receptor γ (PPARγ), the molecular target of a class of insulin
sensitizers, regulates adipocyte differentiation and lipid metabolism. A dominant negative P467L
mutation in the ligand-binding domain of PPARγ in humans is associated with severe ... Cited by 81 - Related articles - BL Direct - All 10 versions
- ►nih.gov AW Norris, L Chen, SJ Fisher, I Szanto, M … - Journal of Clinical …, 2003 - Am Soc Clin Investig Activation of peroxisome proliferator-activated receptor γ (PPARγ) by thiazolidinediones
(TZDs) improves insulin resistance by increasing insulin-stimulated glucose disposal in skeletal
muscle. It remains debatable whether the effect of TZDs on muscle is direct or indirect via ... Cited by 209 - Related articles - BL Direct - All 6 versions
I Barroso, M Gurnell, VEF Crowley, M Agostini, JW … - Nature, 1999 - nature.com Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and reduce
plasma glucose and blood pressure in subjects with type 2 diabetes 1 . Although these agents
can bind and activate an orphan nuclear receptor, peroxisome proliferator-activated ... Cited by 750 - Related articles - BL Direct - All 7 versions
- ►pnas.org W He, Y Barak, A Hevener, P Olson, D … - Proceedings of the …, 2003 - National Acad Sciences Syndrome X, typified by obesity, insulin resistance (IR), dyslipidemia, and other metabolic
abnormalities, is responsive to antidiabetic thiazolidinediones (TZDs). Peroxisome
proliferator-activated receptor (PPAR) γ, a target of TZDs, is expressed abundantly in ... Cited by 282 - Related articles - BL Direct - All 12 versions
AL Hevener, W He, Y Barak, J Le, G Bandyopadhyay, P … - Nature medicine, 2003 - salk.edu 1Department of Medicine, Division of Endocrinology and Metabolism, University of
California, San Diego, La Jolla, California 92093, USA. 2Department of Biology, University of
California, San Diego, La Jolla, California 92093, USA. 3Jackson Laboratory, Bar Harbor, ... Cited by 257 - Related articles - BL Direct - All 8 versions
